Cumulative incidence of relapse-related and non–relapse-related mortality. The cumulative incidence of relapse-related mortality and the cumulative incidence of non–relapse-related mortality for each treatment group are shown. The P value for comparing FAI and FM with respect to relapse-related mortality is .029. The P value for comparing FAI and FM with respect to non–relapse-related mortality is .036. FAI indicates fludarabine, araC, and idarubicin; FM, fludarabine and melphalan.